Abstract
Treatment of patients with metastatic breast cancer (MBC) exposed to anthracyclines and taxanes is challenging. Effective and well-tolerated regimens are required. Gemcitabine plus capecitabine combination was assessed in MBC patients pretreated with anthracyclines and taxanes. A total of 31 patients treated between November 2004 and September 2005 were retrospectively evaluated in 4 institutions. The median age was 48 years (range 29-77). The patients were given gemcitabine 1,000 mg/m(2) on days 1 and 8, and capecitabine 1,500 mg/m(2) twice daily on days 1-14 every 3 weeks. A total of 160 cycles of chemotherapy were administered with a median of 5 cycles per patient (range 2-12). Three patients achieved a partial response (10%) and 8 patients (26%) stable disease. The median time to disease progression was 6 months (95% CI 5-7), with a median survival of 18 months (95% CI 15-21) at a median follow-up of 16 months (range 2-28). One-year and 2-year survival rates were 67 and 28%, respectively. Grade 3-4 toxicities were as follows: neutropenia (n = 11, 35%), nausea and vomiting (n = 4, 13%), hand-foot syndrome (n = 2, 6%), anemia (n = 2, 6%), thrombocytopenia (n = 2, 6%) and asthenia (n = 1, 3%). The combination of gemcitabine pl...Continue Reading
References
Nov 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J CarmichaelA L Harris
Oct 1, 1998·The New England Journal of Medicine·G N Hortobagyi
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Apr 22, 1999·Anti-cancer Drugs·K PossingerM Arning
Feb 3, 2000·Journal of the National Cancer Institute·P TherasseS G Gwyther
Jun 16, 2001·Oncology·M SpielmannP Pouillart
Dec 18, 2001·Cancer·J L BlumB Osterwalder
Jan 26, 2002·Oncology·M BlacksteinA Melemed
Mar 20, 2002·Clinical Breast Cancer·C H SmorenburgJ Verweij
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L ZelekM Spielmann
Feb 3, 2004·Clinical Breast Cancer·Shanu Modi, Andrew D Seidman
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P FumoleauM Namer
Feb 18, 2004·The Breast : Official Journal of the European Society of Mastology·T BrodowiczC C Zielinski
Aug 17, 2004·Journal of Korean Medical Science·Jin-Hee AhnWoo Kun Kim
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHope S Rugo
Jul 9, 2005·Clinical Breast Cancer·Raquel AndresAlejandro Tres
Sep 16, 2005·Cancer Chemotherapy and Pharmacology·V HeinemannG Rauthe
Dec 22, 2005·The Oncologist·Joyce O'Shaughnessy
Feb 14, 2006·Seminars in Oncology·Ian Smith
Sep 27, 2006·Anti-cancer Drugs·Thierry DelozierEsteban Cvitkovic
Feb 1, 2006·Seminars in Oncology·Ian Smith
Citations
Oct 9, 2008·Cancer Chemotherapy and Pharmacology·Steven AttiaGlenn Liu
Aug 30, 2011·Cancer Chemotherapy and Pharmacology·Zhonghua WangXichun Hu
Mar 31, 2012·Breast Cancer Research and Treatment·A H KamalG Kimmick
Nov 27, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E M CiruelosJ Baselga
Dec 12, 2013·Pancreas·Shu-Kun HongKun-Xing Yang
Aug 12, 2014·Cancer Chemotherapy and Pharmacology·Ji Soo ParkHyun Cheol Chung
Sep 29, 2009·Cancer Letters·Xiaoxia GuoWeiguang Wang
Apr 29, 2009·Cancer·Christian WülfingIman A El-Hariry
Aug 26, 2009·Investigational New Drugs·Daniel ChanSoo-Chin Lee
Apr 23, 2010·The Breast Journal·Edgardo Rivera
Oct 21, 2009·Acta Oncologica·Annika MalmströmRonny Westberg
May 14, 2011·Molecular Cancer Therapeutics·Chong ZhangBo Yang